NCT00981409CompletedPhase 3
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 41
- Locations
- 1
- Primary Endpoint
- The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)
Study Overview
Brief Summary
The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of GSK576428 as the initial treatment in subjects with acute PE in an open-label design.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects with a confirmed diagnosis (by Multi detector-row CT [MDCT]) of acute symptomatic PE who are hemodynamically stable (i.e., the condition where anticoagulant therapy alone are indicated) (the time from onset should be no longer than 5 days, and subjects with or without symptomatic DVT are eligible)
- •Age: >=20 years
- •Gender: No restriction Female subjects must either be of non-childbearing potential (post-menopausal >1 year, hysterectomy, or sterilization), or of childbearing potential, has a negative pregnancy test at screening, and agree to use contraception throughout the study period.
- •Hospitalization status: Subjects who are able to stay at the hospital at least during the initial treatment period.
- •Written informed consent from the subject him/herself or his/her legally acceptable representative. Written informed consent from the subject's legally acceptable representative must be obtained if the subject is incapable of giving consent.
Exclusion Criteria
- •Shock or hemodynamic instability*.
- •*: Defined as shock or decreased blood pressure (systolic blood pressure <90 mmHg or >=40 mmHg) lasting for at least 15 minutes and does not represent hemodynamically unstable conditions due to newly emergent arrhythmia, dehydration or sepsis.
- •Right cardiac function failure detected by echocardiography at screening.
- •Requirement for surgical thrombectomy, catheter intervention and thrombolytic therapy for the current PE.
- •Subjects (for example, with free-floating thrombus in the femoral vein or ilium by MDCT at screening) for whom insertion of inferior vena cava filter is indicated or subjects in whom inferior vena cava filter is present.
- •Prior to entry into the study, therapeutic dosage of anticoagulants for more than 24 hours to treat the current episode.
- •Active, clinically significant bleeding
- •Thrombocytopenia (platelet count <10×10⁴/µL at screening)
- •Concurrent conditions with bleeding risk (e.g., ulcer of the gastrointestinal tract, diverticulitis of the gastrointestinal tract, colitis, acute bacterial endocarditis, severe hypertension*, or severe diabetes) or bleeding tendency.
- •*: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg
- •Severe hepatic disorder
- •Known hypersensitivity to heparin, low-molecular-weight heparin (LMWH) or warfarin
- •Previous history of cerebral hemorrhage
- •Brain, spinal, or ophthalmological surgery within 3 months prior to entry into this study
- •Previous history of Heparin-induced thrombocytopenia
- •Patients for whom anticoagulant therapy is contraindicated or who cannot be taken off anticoagulant therapy due to coexistent condition (e.g. prosthetic heart valve implant).
- •Severe renal disorder (serum creatinine >2.0 mg/dL [180 µmol/L] at screening) in a well hydrated subject
- •Documented hypersensitivity to contrast media
- •Use of any contraindicated drug that cannot be combined with the injection of contrast medium [e.g., antihyperglycemic metformin hydrochloride (Glycoran®, Melbin®)]
- •Participation in any other therapeutic drug study or a clinical study within 6 months prior to entry into this study
- •Previous participation in a study of GSK576428
- •Drug or alcohol abuse
- •Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg
- •Recent surgery within 3 days prior to entry into the study
- •Life expectancy <3 months
- •Pregnant women, nursing mothers, women who may be pregnant, or women contemplating pregnancy during the study period
- •Others whom the investigator or subinvestigator considers not eligible for the study
Arms & Interventions
Fondaparinux
Experimental
Intervention: Fondaparinux sodium (Drug)
unfractionated heparin
Other
Intervention: unfractionated heparin (UFH) (Drug)
Outcomes
Primary Outcomes
The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)
Time Frame: From Day 1 to Day 90 (±7 days)
VTE (pulmonary thromboembolism \[PE\] and/or deep vein thromboembolism \[DVT\]) was adjudicated blindly by the Central Independent Adjudication Committee of Efficacy (CIACE).
Secondary Outcomes
- The Percentage of Participants With a Bleeding Event(FPX or UFH treatment period (Days 5-10, on average))
- The Percentage of Participants With Recurrent or New Symptomatic/Asymptomatic Venous Thromboembolism (VTE) (by Type)(From Day 1 to Day 90 (±7 days))
- The Percentage of Participants With Perfusion Lung Scan Results Scored as Improved, no Change, or Worse(Baseline, Days 5-10 (the day when the medication [FPX or UFH] was finished /discontinued) (+/-1))
- Total Perfusion Score at Baseline and Mean Change From Baseline at Days 5-10(Baseline, Days 5-10 (the day when the medication [FPX or UFH] was finished /discontinued) (+/-1))
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese PatientsThrombosis, VenousNCT00911157GlaxoSmithKline39
Completed
Phase 3
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)ThromboembolismNCT00320424GlaxoSmithKline48
Completed
Phase 3
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)Thrombosis, VenousNCT00320398GlaxoSmithKline114
Completed
Phase 3
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid AnalogueHepatitis B, ChronicNCT01480284GlaxoSmithKline166
Completed
Phase 1
A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of AgeTuberculosisNCT06354257GlaxoSmithKline20